Epigenetix
- Biotech or pharma, therapeutic R&D
Clinical stage cancer company with first-in-class multi-targeted oral small molecule drug. Sgns of efficacy in Myelofibrosis with a JAK combination including spleen volume reduction and symptom improvement. Also signs in AML where we are expanding into combinations with Menin inhibitors and BCL-2 inhibitors where there is strong rational and preclinical evidence. We are also adding ET and multiple myeloma patients where there is both preclinical rational and funding. In NUT carcinoma we have a patient that has been treated for 18 months showing long term safety and durability of response.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}